Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2025-03-20 Capital/Financing Update
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
General Updates
Capital/Financing Update Classification · 95% confidence The document is a disclosure letter addressed to stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces the execution of a Shareholders' Agreement and acquisition-related transactions involving subsidiaries of the company. The content focuses on corporate transaction updates rather than financial results, management changes, or detailed reports. It is an announcement of a corporate event related to acquisition and shareholding structure changes, which fits best under Capital/Financing Update (CAP). The document length is short and does not contain financial statements or detailed analysis, so it is not an Annual Report or Interim Report. It is not a merger filing or tender offer form, so it is not M&A Activity or Merger & Acquisition. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-03-20 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges, reporting the receipt of an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for a subsidiary's facility. It references regulatory compliance under SEBI Listing Obligations and Disclosure Requirements. The content is an update on regulatory inspection results and operational status of a facility, not a financial report, earnings release, or management discussion. It is a regulatory announcement informing stakeholders of a compliance event. The document length is short (1673 characters) and it does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2025-03-12 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges, referencing Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It provides a link to the transcript of an Investors and Analyst Meet held on February 24, 2025. The document itself does not contain the transcript but only announces its availability. The length is only 1138 characters, which is very short and consistent with an announcement rather than the full transcript. According to the MENU VS MEAL RULE, this is an announcement of a report (the transcript) rather than the transcript itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2025-03-04 English
Rumour Verification - Regulation 30(11)
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges under SEBI Listing Regulations, providing clarification on media reports about a legal matter involving the Chairman. It contains no financial data, no report or presentation, and no voting or dividend information. It is an update related to legal proceedings but does not constitute a full legal proceedings report or detailed litigation filing. Given the nature of the content as a regulatory disclosure clarifying news and ongoing investigation, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length is short and it is not a report publication announcement or certification. Therefore, the classification is RNS with high confidence.
2025-02-25 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement informing that the audio recording of an Investors and Analysts Meeting held on February 24, 2025, is available on the company's website. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure obligations. The document does not contain any financial data, detailed presentation content, or transcript text. It is essentially a notification about the availability of the audio recording rather than the transcript or presentation itself. According to the classification rules, such announcements about availability or publication of materials related to investor meetings fall under Regulatory Filings (RNS) as a general regulatory announcement and do not qualify as a Call Transcript (CT) or Investor Presentation (IP). The document length is short (1327 characters), reinforcing that it is an announcement rather than the full content of the meeting.
2025-02-24 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'Investor & Analyst Meet Feb’25' for Jubilant Pharmova Limited, dated February 24, 2025. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosures to stock exchanges. The content includes company overview, business segments, leadership, financial highlights, growth drivers, and strategic vision. It is clearly a presentation prepared for investors and analysts, focusing on financials, strategy, and market position. The document is about 15,000 characters long, contains no standalone financial statements or audit information, and is not an announcement of a report but the actual presentation material. Therefore, it fits the category of Investor Presentation (IP).
2025-02-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.